# Enrofloxacin Baytril Dose: Fluoroquinolone Dose and Tendon Warning ## Key Takeaways - Enrofloxacin (Baytril) is a bactericidal, concentration-dependent fluoroquinolone antibiotic with a broad spectrum of activity, but its efficacy is critically linked to achieving optimal pharmacokinetic/pharmacodynamic (PK/PD) targets (Cmax/MIC and AUC/MIC). - While the approved label dose for dogs and cats is 5 mg/kg once daily, current research supports higher doses (e.g., 10 mg/kg IV q24h in critically ill dogs) to achieve therapeutic goals and mitigate resistance selection, though this necessitates careful monitoring. - A significant safety concern is cartilage damage in juvenile animals, contraindicating enrofloxacin use in young dogs and cats; in cats, ocular toxicity (retinal degeneration) is a serious risk, potentially occurring even at label doses. - Enrofloxacin pharmacokinetics exhibit species-specific and age-dependent variability, with dose-dependent clearance and prolonged half-lives observed in calves, and temperature-dependent elimination in fish, necessitating tailored dosing strategies. - The risk of tendon rupture, a known fluoroquinolone side effect in humans, is considered low in adult dogs and cats but remains a theoretical concern, particularly with concurrent corticosteroid use, while cartilage damage in juveniles is a direct contraindication. - Responsible use of enrofloxacin is paramount due to its classification as a critically important antimicrobial for human medicine, with environmental persistence and the selection of antimicrobial resistance being significant public health and ecological considerations. --- Enrofloxacin, marketed under the brand name Baytril, is a broad-spectrum fluoroquinolone antibiotic used extensively in veterinary medicine across dogs, cats, birds, reptiles, fish, and livestock. It is bactericidal and concentration-dependent, meaning that higher peak concentrations relative to the minimum inhibitory concentration (MIC) of the target bacterium correlate with better bacterial killing and a lower likelihood of resistance selection. The approved label dose for dogs and cats is 5 mg/kg once daily, but current pharmacodynamic research, especially in critically ill patients, supports higher doses of 10 mg/kg or more for difficult infections. This article provides a source-grounded review of enrofloxacin dosing, pharmacokinetics, safety warnings (especially regarding tendons, cartilage, and the eyes), and clinical decision-making for veterinarians and informed pet owners. **Owner-facing triage summary:** If your veterinarian has prescribed enrofloxacin (Baytril), give the exact dose prescribed, at the same time each day, with food if vomiting occurs. Do not give more than prescribed, do not double a missed dose, and do not use this medication without a veterinary examination. Stop the medication and contact your veterinarian immediately if your pet develops vomiting, diarrhoea (especially with blood), loss of appetite, weakness, difficulty walking, sudden blindness, or eye changes. Enrofloxacin is not approved for use in young, growing puppies and kittens (under 8 months in dogs, under 12 months in large-breed dogs, and under 7 months in cats) due to the risk of cartilage damage. It is also not approved for cats with known kidney disease or seizures without close monitoring. ## At a Glance: Enrofloxacin Key Facts | Parameter | Typical Value or Recommendation | Source / Context | |------|----------------|---------| | **Class** | Fluoroquinolone antibiotic | Bactericidal, concentration-dependent | | **Common Brands** | Baytril, generic enrofloxacin | Various manufacturers | | **Label Dose (Dogs/Cats)** | 5 mg/kg PO or IV once daily | Historical label; often exceeded in practice | | **Higher Dose (Dogs)** | 10 mg/kg IV q24h for critical illness | Shown to achieve PK/PD targets in critically ill dogs [1] | | **Higher Dose (Calves)** | 10 mg/kg IV | Studied for PK; dose-dependent clearance [2] | | **Oral Absorption** | Rapid; Cmax ~1.33 µg/mL at ~0.59h in tilapia | Variable by species and formulation [3] | | **Active Metabolite** | Ciprofloxacin | Conversion ratio varies by species and age [4][2] | | **Half-life (Calves)** | 2.41 to 3.47 h (IV) | Dose-dependent [2] | | **Half-life (Fish)** | 27.38 to 42.01 h | Temperature-dependent [5] | | **Major Warnings** | Cartilage damage (young animals), retinal degeneration (cats), tendon rupture (humans, caution in animals) | See safety section | | **Breakpoints** | Revised feline breakpoints are lower than current CLSI values | PK-PD derived [6] | ## Understanding Enrofloxacin: Mechanism of Action and Spectrum Enrofloxacin works by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This action is bactericidal and concentration-dependent. The ratio of peak plasma concentration (Cmax) to MIC, and the area under the curve (AUC) to MIC, are the primary pharmacokinetic/pharmacodynamic (PK/PD) indices that predict clinical efficacy and the suppression of resistance. The spectrum of activity includes many Gram-negative and some Gram-positive bacteria, including *Escherichia coli*, *Pasteurella multocida*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Staphylococcus* spp. However, susceptibility is not universal, and breakpoints are species-specific. A 2026 study by Papich and colleagues highlighted that the current feline breakpoints for enrofloxacin and marbofloxacin are discordant with the revised canine breakpoints published in 2023 [6]. Using a PK-PD approach, the authors suggest that the feline breakpoints for Enterobacterales, *P. aeruginosa*, *Staphylococcus* spp., and *P. multocida* should be two dilutions lower than the current CLSI values [6]. This means that some feline isolates previously reported as susceptible would now be classified as resistant, potentially changing therapeutic choices. This is a critical reminder that a dose that worked for one infection may not be adequate for another, and culture and susceptibility testing should guide therapy whenever possible. ## Enrofloxacin Dosing: Species and Clinical Scenarios Dosing of enrofloxacin is not a one-size-fits-all calculation. It depends on the species, the severity of infection, the susceptibility of the pathogen, and the patient's organ function. The following sections summarize the evidence from the approved source packet. ### Dogs: From Label Doses to Critical Care The label dose for dogs is 5 mg/kg once daily. However, a prospective observational study by Goggs and colleagues (2025) evaluated the pharmacokinetics of enrofloxacin in 19 critically ill dogs after a standardized dose of 10 mg/kg IV q24h [1]. The study found considerable between-[dog](/knowledge/veterinary-medicine/clinical-methods/dog) variation in PK parameters, which is expected in critical illness. Despite this, the pharmacodynamic analysis suggested that 10 mg/kg IV q24h would likely achieve effective treatment for susceptible and susceptible dose-dependent bacterial infections, and the achieved concentrations may be sufficient to reduce the risk of antimicrobial resistance development [1]. This study supports the use of higher doses in severely ill dogs, but it also emphasizes the need for careful monitoring and potentially therapeutic drug monitoring in individual patients. A separate study evaluated a long-acting, tasteless oral formulation of enrofloxacin in dogs, comparing a 15 mg/kg single dose of the experimental minispheres to a 10 mg/kg/day dose of the reference flavored tablet [7]. The minispheres concealed in pate achieved the highest Cmax and AUC0-48. When assessing PK/PD ratios against a breakpoint of 0.5 µg/mL (Cmax/MIC ≥ 10-12 and AUC0-24/MIC ≥ 125), only the experimental minispheres concealed in pate met the target [7]. This highlights that not only the dose but also the formulation and the way it is administered can affect whether therapeutic concentrations are achieved. ### Cats: Dosing and the Ocular Warning Enrofloxacin is approved for use in cats, but it carries a well-documented risk of ocular toxicity, specifically retinal degeneration. A scoping review by Weese and Weese (2025) identified reports of enrofloxacin-associated adverse ocular events in 163 cats [8]. The most common clinical signs were loss of vision, mydriasis (dilated pupils), and altered pupillary light responses. On ophthalmologic examination, increased tapetal reflectivity, retinal vessel attenuation, and retinal degeneration were the most common abnormalities [8]. Most cats had permanent blindness or altered vision. Critically, while most affected cats received doses well in excess of the current label recommendation (5 mg/kg/day), 15 out of 103 cats (14%) for which dosing data were available were reported to have received ≤ 5 mg/kg per day [8]. This indicates that even at label doses, there is a risk of ocular toxicity in cats, and this risk increases with higher doses. The authors note that suspected enrofloxacin-associated ocular disease is a serious concern and that the benefit-risk ratio should be carefully considered for each feline patient [8]. The revised feline breakpoints suggested by Papich et al. (2026) are also relevant here [6]. If a [cat](/knowledge/veterinary-medicine/clinical-methods/cat) has an infection caused by an isolate with a higher MIC, a higher dose of enrofloxacin might be considered to achieve the PK/PD target, but this would increase the risk of ocular toxicity. This is a clinical dilemma that requires careful judgment and discussion with the owner. ### Calves and Food Animals: Age and Dose-Dependent Pharmacokinetics Enrofloxacin is used in cattle, and its pharmacokinetics are influenced by both age and dose. A study by Corum et al. (2026) examined the influence of age on enrofloxacin and ciprofloxacin pharmacokinetics in calves receiving a single IV dose of 10 mg/kg [4]. In one-month-old calves, the volume of distribution at steady state (Vdss) was 1.44 L/kg, total clearance (ClT) was 0.42 L/h/kg, and the elimination half-life (t1/2λz) was 2.52 h. Notably, the AUC of enrofloxacin increased and clearance decreased in the older age groups (four and eight months), while the Vdss significantly decreased in eight-month-old calves [4]. The conversion ratio of enrofloxacin to ciprofloxacin was highest in one-month-old calves (43.39%) and diminished in older calves [4]. This suggests that younger animals may metabolize enrofloxacin more extensively to ciprofloxacin, and that dosing adjustments may be needed based on age. Another study by Uney et al. (2026) investigated dose-dependent changes in enrofloxacin pharmacokinetics in calves given IV doses of 2.5, 5, or 10 mg/kg [2]. The AUC0-last/dose increased in a dose-dependent manner, and the elimination half-life was prolonged from 2.41 to 3.47 hours as the dose increased. Total body clearance decreased significantly with increasing dose, while the volume of distribution remained comparable [2]. This non-linearity in pharmacokinetics means that doubling the dose may result in a more than proportional increase in drug exposure, which has implications for both efficacy and safety. The conversion ratio of enrofloxacin to ciprofloxacin was consistent (26-28%) across the dose groups [2]. ### Poultry and Fish: PK/PD Integration for Food-Producing Species Enrofloxacin is widely used in poultry and aquaculture. A study by Felix et al. (2025) used a nonlinear mixed-effects model to establish a pharmacokinetic model of enrofloxacin in broilers and predict the effectiveness of various oral dosing regimens (10, 20, 30, and 50 mg/kg) across a distribution of *E. coli* MICs [9]. The best-fit model was a two-compartment model with first-order absorption and linear elimination. The probability of target attainment (PTA) was evaluated for two PK/PD targets (fAUC24/MIC ≥ 125 and fAUC24/MIC = 28.32) [9]. This modeling approach is essential for optimizing dosing regimens to achieve clinical cure while minimizing the selection of resistance. In aquaculture, enrofloxacin pharmacokinetics are highly variable. In Nile tilapia, a single oral dose of 10 mg/kg resulted in rapid absorption with a Cmax of 1.33 µg/mL at 0.59 hours, and extensive tissue distribution, particularly in bile and intestine [3]. Elimination half-lives varied among tissues, with prolonged persistence in skin (693.18 h) and gills (237.47 h), indicating slow depletion and a need for long withdrawal times [3]. The study also reported that the MIC of enrofloxacin for *Aeromonas hydrophila* was 0.20 µg/mL, while *Streptococcus agalactiae* was less sensitive (MIC: 1.56 µg/mL) [3]. In black rockfish, the elimination half-life of enrofloxacin increased from 27.38 h at 13°C to 42.01 h at 22°C, and the study suggested that a single oral dose of 10 mg/kg may not achieve optimal therapeutic indices against certain pathogens, underscoring the need for repeated dosing [5]. These studies highlight the importance of species-specific and temperature-specific dosing in aquaculture. ### Exotic and Non-Traditional Species Enrofloxacin is also used in exotic species, though published pharmacokinetic data are often limited. A study in land snails (*Cornu aspersum maxima*) evaluated the pharmacokinetics of enrofloxacin and ciprofloxacin after various routes of administration [10]. After a single intrahaemolymphatic dose of 1 mg/kg, enrofloxacin concentrations remained above the limit of quantification for up to 72 hours. The elimination half-life was 15-19 hours, and bioavailability was higher from medicated wafers (74.6%) than from gavage (27.7%) [10]. After multiple dosing (10 mg/kg via gavage for five days), enrofloxacin accumulated predominantly in the hepatopancreas, with persistence in tissues beyond 240 hours [10]. This study demonstrates that enrofloxacin can be absorbed and distributed in invertebrates, but the clinical relevance and optimal dosing for snails remain to be established. A study in olive baboons (*Papio anubis*) demonstrated that orogastrically administered injectable enrofloxacin at 10 mg/kg resulted in higher serum levels than intramuscular administration [11]. This finding supports the use of oral administration of the injectable formulation as a less stressful alternative for nonhuman primates [11]. In sugar gliders, enrofloxacin was administered subcutaneously as part of a perioperative protocol, but no specific pharmacokinetic data were reported in that study [12]. ## The Tendon Warning: What Is the Evidence? The warning about fluoroquinolone-associated tendon damage is primarily derived from human medicine, where these drugs are associated with an increased risk of tendonitis and tendon rupture, particularly of the Achilles tendon. This risk is higher in older adults, those taking corticosteroids, and those with kidney disease. In veterinary medicine, the concern is more focused on cartilage damage in juvenile animals, which is a well-documented and dose-dependent effect of fluoroquinolones. This has led to the contraindication of enrofloxacin in young, growing dogs and cats. While the tendon warning is a major label concern for human fluoroquinolones, the direct evidence for tendon rupture in dogs and cats treated with enrofloxacin is less well-documented in the sources provided. However, the potential for tendon and cartilage damage is a class effect, and caution is warranted. The primary safety warnings for enrofloxacin in veterinary patients are: 1. **Cartilage damage in juvenile animals:** This is the most significant concern and is the basis for the age restrictions on the label. The exact mechanism involves the chelation of magnesium ions and the subsequent disruption of chondrocyte function, leading to apoptosis and cartilage erosion. 2. **Ocular toxicity in cats:** As detailed above, this can occur even at label doses and is a potentially irreversible adverse event [8]. 3. **Gastrointestinal upset:** Vomiting, diarrhoea, and loss of appetite are common side effects. 4. **Neurological effects:** Seizures have been reported, particularly in animals with underlying kidney disease or those receiving high doses. 5. **Photosensitivity:** Rarely, skin reactions to sunlight can occur. The risk of tendon damage in growing animals is a direct contraindication to use. For adult animals, the risk of tendon rupture is considered low, but it is still a theoretical concern, especially in animals with predisposing factors such as concurrent corticosteroid use or underlying musculoskeletal disease. The decision to use enrofloxacin should always involve a risk-benefit analysis, and alternative antibiotics should be considered when the risk is deemed unacceptable. ## Environmental and Public Health Considerations The use of enrofloxacin in food-producing animals has significant public health implications due to the potential for selection of antimicrobial resistance. The World Health Organization (WHO) classifies fluoroquinolones as critically important antimicrobials for human medicine. The use of enrofloxacin in food animals is therefore subject to regulation and restrictions in many countries. Several studies in the source packet highlight the environmental impact of enrofloxacin. It is a commonly identified veterinary pharmaceutical in global aquaculture products, and short-term therapeutic applications at recommended doses can exert adverse effects on farmed fish, including intestinal immunostimulation and microbiota dysbiosis [13]. Chronic exposure to environmentally relevant concentrations of enrofloxacin in marine medaka reorganizes the gut-lipid-resistome steady state, with effects persisting even after a withdrawal period [14]. Furthermore, environmental enrofloxacin exposure has been identified as a modifiable driver of mitochondria-mediated intestinal aging and barrier dysfunction in zebrafish models [15]. These studies underscore the need for responsible use and proper disposal of veterinary antibiotics to minimize environmental contamination. The presence of enrofloxacin in wastewater and the environment also contributes to the spread of antibiotic resistance genes. A study on the combined toxicity of neonicotinoid insecticides and fluoroquinolone antibiotics in human neuroblastoma cells found that mixtures of enrofloxacin and ofloxacin produced synergistic toxicity, highlighting the potential risks of environmental mixtures [16]. Advanced oxidation processes, such as photocatalysis using TiO2-ZnO nanocomposites, are being developed to degrade enrofloxacin and other antibiotics in wastewater, but their practical application is still under investigation [17][18]. ## Antimicrobial Resistance: A Growing Threat The use of enrofloxacin, especially at subtherapeutic doses or for inappropriate durations, is a major driver of antimicrobial resistance. The study by Goggs et al. (2025) specifically noted that inadequate plasma concentrations select for resistance among Enterobacterales and *Pseudomonas aeruginosa* [1]. This is a critical concern in both companion animals and food-producing animals. The combination of enrofloxacin with other antibiotics is sometimes used to broaden the spectrum or achieve synergy. A study by Wei et al. (2026) evaluated the PK/PD relationships and development of resistance of enrofloxacin and cefquinome in combination therapy against *Klebsiella pneumoniae* in chicks [19]. The study found that a split-dose group receiving 20 mg/kg of enrofloxacin in combination with 20 mg/kg of cefquinome was significantly more effective than single-dose groups, suggesting that combination therapy and dosing schedule can impact efficacy and resistance development [19]. However, the use of fixed-dose combination antibiotics in veterinary medicine is increasingly scrutinized due to concerns about unproven efficacy, inappropriate dosing, and safety [20]. A review of veterinary drug registries in Africa found that 27.5% of registered antibiotic products were fixed-dose combinations, and many lacked a clear therapeutic rationale [20]. This highlights the need for evidence-based regulation and judicious use of combination therapies. ## Limitations and When to Contact a Veterinarian This article provides a comprehensive overview of enrofloxacin dosing and safety based on the available scientific literature. However, it is not a substitute for professional veterinary advice. The information presented here cannot predict the outcome for an individual animal, as it does not account for the specific pathogen, the patient's overall health status, concurrent medications, or breed-specific sensitivities. **You should contact your veterinarian immediately if your pet exhibits any of the following:** - **Severe vomiting or diarrhoea, especially if it contains blood.** - **Sudden loss of appetite or refusal to drink water.** - **Weakness, lethargy, or difficulty walking.** - **Signs of an allergic reaction, such as facial swelling, hives, or difficulty breathing.** - **Any change in vision, such as bumping into objects, dilated pupils, or apparent blindness (especially in cats).** - **Seizures or tremors.** - **Any other unusual behavior or symptoms.** Never adjust the dose or stop the medication without consulting your veterinarian. If you miss a dose, give it as soon as you remember, but skip it if it is almost time for the next dose. Do not give a double dose. ## Frequently Asked Questions ### What is the standard enrofloxacin (Baytril) dose for a dog? The label dose for dogs is 5 mg/kg once daily, but higher doses of 10 mg/kg IV q24h are often used in critically ill dogs to achieve optimal pharmacodynamic targets and reduce the risk of resistance [1]. ### Is enrofloxacin safe for puppies and kittens? No, enrofloxacin is generally not recommended for young, growing animals due to the risk of cartilage damage. It is contraindicated in puppies under 8 months of age (and under 12 months for large-breed dogs) and kittens under 7 months of age. ### What is the most serious side effect of enrofloxacin in cats? The most serious side effect is retinal degeneration, which can lead to permanent blindness. This can occur even at label doses of 5 mg/kg/day, although the risk is higher with larger doses [8]. ### Can enrofloxacin cause tendon damage in dogs? While tendon rupture is a well-documented side effect of fluoroquinolones in humans, the primary concern in dogs is cartilage damage in juveniles. The risk of tendon rupture in adult dogs is considered low, but it is a theoretical concern, especially with concurrent corticosteroid use. ### How is enrofloxacin eliminated from the body? Enrofloxacin is primarily eliminated through renal and hepatic pathways. It is partially metabolized to ciprofloxacin, which is also an active antibiotic. The elimination half-life varies significantly by species, age, and dose [4][2][5]. ### Can I give my pet human fluoroquinolone antibiotics like ciprofloxacin instead? No, you should never give human medications to your pet without veterinary approval. The dose, formulation, and safety profile are different. Enrofloxacin is the veterinary-specific fluoroquinolone, and its use should be directed by a veterinarian. ### What should I do if my pet vomits after receiving enrofloxacin? If your pet vomits shortly after receiving the medication, contact your veterinarian for advice. They may recommend giving the medication with a small amount of food or an anti-emetic. Do not re-dose without instructions. ### How long does it take for enrofloxacin to start working? Enrofloxacin is rapidly absorbed and reaches peak plasma concentrations within a few hours of oral administration [3]. You may see an improvement in clinical signs within 24 to 48 hours, but it is important to complete the full course of antibiotics as prescribed, even if your pet appears to be feeling better. ## Veterinary Disclaimer **This article is educational and is not a substitute for veterinary diagnosis or treatment.** The information provided here is for general informational purposes only and should not be used to diagnose or treat any animal health condition. Always consult with a qualified veterinarian regarding any questions you may have about your pet's health or before starting, changing, or stopping any treatment. Never disregard professional veterinary advice or delay in seeking it because of something you have read in this article. ## Sources [1] [Routine Doses of Enrofloxacin Achieve Pharmacodynamic Target Likely to Treat Susceptible and Susceptible Dose-Dependent Bacterial Infections in Critically Ill Dogs.](https://pubmed.ncbi.nlm.nih.gov/40387269/) [2] [Pharmacokinetic Profiles of Enrofloxacin and Its Metabolite Ciprofloxacin Administered by Different Doses in Calves.](https://pubmed.ncbi.nlm.nih.gov/42083390/) [3] [Pharmacokinetics and Tissue Residue Profiles of Enrofloxacin in Nile Tilapia Oreochromis niloticus Following a Single Oral Administration.](https://pubmed.ncbi.nlm.nih.gov/41557488/) [4] [The Influence of Age on the Pharmacokinetics of Enrofloxacin and Ciprofloxacin in Calves.](https://pubmed.ncbi.nlm.nih.gov/42357736/) [5] [Pharmacokinetics of Enrofloxacin and Its Metabolite Ciprofloxacin in Black Rockfish (Sebastes schlegelii) Following a Single Oral Administration at Two Water Temperatures.](https://pubmed.ncbi.nlm.nih.gov/40804767/) [6] [The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates.](https://pubmed.ncbi.nlm.nih.gov/41020640/) [7] [Pharmacokinetic evaluation of a long-acting, tasteless oral formulation of enrofloxacin in dogs.](https://pubmed.ncbi.nlm.nih.gov/41246413/) [8] [Enrofloxacin-associated ocular disease in cats: A scoping review.](https://pubmed.ncbi.nlm.nih.gov/41584252/) [9] [Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens.](https://pubmed.ncbi.nlm.nih.gov/41200291/) [10] [Pharmacokinetics and residue depletion of enrofloxacin and its metabolite ciprofloxacin in land snails (Cornu aspersum maxima).](https://pubmed.ncbi.nlm.nih.gov/42440879/) [11] [Noninferiority of Orogastrically Administered Enrofloxacin Compared to Intramuscular Administration in the Olive Baboon (Papio anubis).](https://pubmed.ncbi.nlm.nih.gov/41057209/) [12] [Combination of Dexmedetomidine and Low-Dose Ketamine in 4 Sugar Gliders (Petaurus breviceps) Undergoing Elective Castration.](https://pubmed.ncbi.nlm.nih.gov/40872650/) [13] [Therapeutic-Dose Enrofloxacin Immersion Induces Intestinal Immunostimulation and Microbiota Dysbiosis in Juvenile Black Seabream Acanthopagrus schlegelii.](https://pubmed.ncbi.nlm.nih.gov/42229880/) [14] [Early-life and lifelong exposure to environmentally relevant enrofloxacin reorganizes a proteobacteria-centered gut-lipid-resistome steady state in marine medaka.](https://pubmed.ncbi.nlm.nih.gov/42019450/) [15] [Environmental Enrofloxacin Exposure as a Modifiable Driver of Mitochondria-Mediated Intestinal Aging and Barrier Dysfunction.](https://pubmed.ncbi.nlm.nih.gov/42059464/) [16] [Enhanced Toxicity Induced by Combined Exposure to Neonicotinoid Insecticides and Fluoroquinolone Antibiotics in Human Neuroblastoma SK-N-SH Cells.](https://pubmed.ncbi.nlm.nih.gov/41893464/) [17] [Enhanced visible-light photocatalysis of a senary mixture of antibiotics using a low-dose of TiO(2)-ZnO nanocomposite.](https://pubmed.ncbi.nlm.nih.gov/40480352/) [18] [Temperature-tuned Co-ZIF-67@Fe-MIL(101) derived catalysts for advanced peroxymonosulfate activation in enrofloxacin removal from water.](https://pubmed.ncbi.nlm.nih.gov/41525829/) [19] [Pharmacokinetic/pharmacodynamic relationships and development of resistance of enrofloxacin and cefquinome in combination therapy against Klebsiella pneumoniae in chicks.](https://pubmed.ncbi.nlm.nih.gov/41724978/) [20] [Veterinary fixed-dose antibiotics in Africa: a need for evidence-based regulation.](https://pubmed.ncbi.nlm.nih.gov/42316266/) ## Related Clinical & Scientific Guides * [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight) * [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule) * [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)